Akebia Q1 Vafseo Sales Hit $15.8M with 60% Patient Growth, FSGS Trial Advances
AKBA•Vafseo net product revenues rose to $15.8 million in Q1 2026, with prescribers up 28% to 1,025 and patients up 60% quarter-over-quarter. Akebia’s pipeline progressed with Phase 2 praliciguat enrollment in FSGS and a planned Phase 2 AKB-097 basket trial in IgA nephropathy and lupus nephritis.
1. Q1 Vafseo Commercial Growth
Vafseo (vadadustat) net product revenues climbed to $15.8 million in Q1 2026, contributing to total net product revenues of $52.0 million year-to-date. The number of prescribers rose by 28% to about 1,025 and patient counts increased 60% over Q4 2025, with first refill adherence around 86% under observed dosing.
2. Clinical Pipeline Progress
Enrollment is underway in the Phase 2 praliciguat trial for focal segmental glomerulosclerosis, targeting approximately 60 patients. In the second half of 2026, Akebia plans to launch a Phase 2 open-label basket study of AKB-097 in IgA nephropathy, lupus nephritis and C3 glomerulopathy.
3. Upcoming Data Catalysts
Topline results from the VOCAL Phase 3b trial of three-times-weekly Vafseo dosing versus ESAs are expected in Q4 2026. Early 2027 will bring topline data from the VOICE Phase IV study of over 2,100 patients assessing a hierarchical composite endpoint of mortality and hospitalization.
